Showing results (51-60 of 5,040) with videos related to

Sort By:
Pageof 504
Multiple Sclerosis and Related Disorders|December 24, 2021
"I'm walking into the unknown": Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatmentGina Carey, Neil Wilson, Jessie Janssen, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
A novel disease specific scale to characterize the symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis: A real-world studyMarion Azoulai, Tiphaine Lévy-Heidmann, Valentin Morisseau, et al.
Multiple Sclerosis and Related Disorders|February 17, 2022
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysisMozhde Askari, Omid Mirmosayyeb, Elham Moases Ghaffary, et al.
Multiple Sclerosis and Related Disorders|September 25, 2021
Comparing fall detection methods in people with multiple sclerosis: A prospective observational cohort studyAndrea Hildebrand, Peter G Jacobs, Jonathon G Folsom, et al.
Multiple Sclerosis and Related Disorders|September 27, 2021
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosisFrederik Novak, Anna Christine Nilsson, Christian Nielsen, et al.
Multiple Sclerosis and Related Disorders|October 7, 2021
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosisMark S Freedman, Dominic Jack, Zuzana Murgašová, et al.
Multiple Sclerosis and Related Disorders|October 8, 2021
Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany - A registry-based/multicentric cohort studyNiklas Frahm, David Ellenberger, Firas Fneish, et al.
Multiple Sclerosis and Related Disorders|February 5, 2022
Identification of miRNAs and their potential effects on multiple sclerosis related pathways using ın silico analysisBurcin Erkal, Senay Vural Korkut
Multiple Sclerosis and Related Disorders|February 5, 2022
Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating diseaseMahmoud A AbdelRazek, Marcel Casasola, Roohallah Mollashahi, et al.
Multiple Sclerosis and Related Disorders|June 23, 2019
Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoireShiri Blumenfeld-Kan, Elsebeth Staun-Ram, Ariel Miller
Pageof 504